Immix Biopharma

Immix Biopharma

ImmixBio was founded in 2012 by a visionary physician/scientist, a world-renown pharmacology expert, a seasoned biotechnology patent attorney and an impact-driven founding family office. We are developing an entirely new class of Tissue-Specific Therapeutics, or TSTx, which we believe will replace first-line therapies across a multitude of cancer indications.

Content by Immix Biopharma

Cancer cell image
| 1 min read
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A scientist in a white lab coat looking into a microscope in a brightly lit modern laboratory.
Learn how developmental and reproductive toxicology study selection supports regulatory decision-making and generates meaningful nonclinical safety data.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue